- Home
- GCI vs TBPH Comparison
GCI vs TBPH Comparison
Compare GCI & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- TBPH
- Stock Information
- Founded
- GCI 1997
- TBPH 2013
- Country
- GCI United States
- TBPH United States
- Employees
- GCI N/A
- TBPH N/A
- Industry
- GCI Newspapers/Magazines
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- TBPH Health Care
- Exchange
- GCI Nasdaq
- TBPH Nasdaq
- Market Cap
- GCI 549.7M
- TBPH 464.5M
- IPO Year
- GCI N/A
- TBPH N/A
- Fundamental
- Price
- GCI $3.54
- TBPH $8.62
- Analyst Decision
- GCI Buy
- TBPH Buy
- Analyst Count
- GCI 3
- TBPH 3
- Target Price
- GCI $5.70
- TBPH $11.33
- AVG Volume (30 Days)
- GCI 2.1M
- TBPH 222.8K
- Earning Date
- GCI 05-01-2025
- TBPH 05-12-2025
- Dividend Yield
- GCI N/A
- TBPH N/A
- EPS Growth
- GCI N/A
- TBPH N/A
- EPS
- GCI N/A
- TBPH N/A
- Revenue
- GCI $2,509,315,000.00
- TBPH $64,381,000.00
- Revenue This Year
- GCI N/A
- TBPH $51.09
- Revenue Next Year
- GCI N/A
- TBPH N/A
- P/E Ratio
- GCI N/A
- TBPH N/A
- Revenue Growth
- GCI N/A
- TBPH 12.12
- 52 Week Low
- GCI $2.35
- TBPH $7.44
- 52 Week High
- GCI $5.93
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- GCI 60.39
- TBPH 42.54
- Support Level
- GCI $2.61
- TBPH $8.44
- Resistance Level
- GCI $3.01
- TBPH $8.82
- Average True Range (ATR)
- GCI 0.26
- TBPH 0.44
- MACD
- GCI 0.09
- TBPH 0.00
- Stochastic Oscillator
- GCI 79.84
- TBPH 55.47
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).